Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
IperionX ASX Surge Puts Titanium Progress Under the Spotlight
Highlights
Titanium Output Accelerates
IperionX Limited (ASX: IPX) traded at a current market price (CMP) of AU$2.280, registering a surge of 8.5%, as its quarterly update dated 29 October 2026 detailed production gains, technology improvements and expanding defence programs.
September-quarter HAMR powder output reached 8.7 tons, compared to 1.4 tons in June. Closing inventories comprised 19 tons of finished powder and 207 tons of scrap feedstock. Validated furnace capacity exceeded 200 tons annually, with powder meeting or surpassing Grade 5 specifications. IperionX manufactured 1,500 fasteners and commissioned an additional sintering furnace.
GenX Demonstrates Efficiency
GenX processed over 500 kilograms during four continuous runs spanning 41 hours. All valid samples satisfied ASTM oxygen specifications.
Compared to batch HAMR under equivalent runtime conditions, throughput increased sixfold. Power use declined over 75%, magnesium consumption fell over 45%, and hydrogen requirements dropped over 60% per kilogram. Annualised capacity reached approximately 100 tons, pending production-line integration.
Defence And Funding
Army Task Order 2 carries a US$18.5 million base value, initially funded at US$11.5 million. Options could increase its value to US$25.4 million. The company also progressed its planned expansion towards 1,400 tons of annual capacity.
Cash stood at US$63.0 million, compared to US$35.2 million, alongside US$33.7 million in obligated reimbursable funding. Operating cash outflow was US$12.6 million. The public offering generated US$50.0 million gross and approximately US$46.1 million net.
Titan’s study projected US$813 million after-tax NPV8, 39.4% IRR, 3.6-year payback and US$1.9 billion cumulative after-tax free cash flow over 14 years. Atlas acquisition consideration was US$3 million.
Outlook
IperionX’s progress now depends on translating validated production capabilities into consistent customer deliveries and recurring orders. Priorities include integrating GenX capacity, expanding downstream manufacturing and completing customer qualification. Defence programs provide potential opportunities, although additional orders remain dependent on testing and procurement decisions. Available cash and reimbursable government funding support expansion, while operating cash outflows underline the importance of disciplined spending, reliable execution and stronger commercial conversion over coming quarters.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au